Tag Archives: Johnson & Johnson

Top Stories for Week of August 24, 2020

      No Comments on Top Stories for Week of August 24, 2020

Top FDA official in charge of overseeing new COVID-19 vaccines says he’ll resign if agency is pressured into a premature approval. A top US health regulator who will help decide… Read more »

Top Stories for Week of June 8, 2020

White House picks five COVID-19 vaccine candidates for Warp Speed initiative. The Trump administration has chosen five companies as the most likely contenders to produce a vaccine for the coronavirus, senior officials… Read more »

Top Stories for Week of May 4, 2020

Trump’s Warp-Speed Plan aims to produce COVID-19 vaccine this year. US President Donald Trump said on Thursday (April 30, 2020) the US plans to accelerate the development of a coronavirus… Read more »

Sackler Family, Purdue Pharma not the only ones to blame for US opiod crisis. Not by a long shot.

The News: After months of negotiations and threats, Purdue Pharma LP (Stamford CT) finally filed for bankruptcy earlier this week. But it’s hardly a done deal, according to The New York Times…. Read more »

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

South Korea’s Celltrion Inc. (Incheon) gets EU green light for Herceptin biosimilar

The News: Celltrion Inc. said on February 14, 2018 that it has received approval to sell its replica version of Roche Holding AG’s (Basel CHE) breast-cancer blockbuster Herceptin in Europe…. Read more »

From across the pond, 2017’s brightest European biotech stars; perhaps under US’s radar, but still ready to soar?

Many said good riddance to 2016 for biotech and pharma; things could only get better this year–and the European industry didn’t disappoint, says Labiotech.eu, the quintessential industry observer and news… Read more »

Humdrum, stodgy Pfizer suddenly turns heads with partial drug-pipeline spinoff; old dog apparently can learn new tricks.

The News: Pfizer Inc. (NYC) on Monday (September 25, 2017) announced that it is spinning off a new company, SpringWorks Therapeutics LLC, to develop several drugs for rare diseases that… Read more »